In addition, pharmacological treatment with an ARF6 inhibitor (NAV-2729) blocked ARF6 activation in an experimental autoimmune encephalomyelitis mouse model, enhancing BCNSB function, reversing EndoMT, and reducing disease progression. Here, ARF6 is linked to experimental autoimmune encephalomyelitis.